Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Balance Sheets

v3.7.0.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2017
Dec. 31, 2016
Current Assets    
Cash and cash equivalents $ 13,471 $ 19,055
Prepaid expenses and other current assets 3,366 2,515
Total Current Assets 16,837 21,570
Property and equipment, net 859 905
Deposits and other assets 23 23
Total Assets 17,719 22,498
Current Liabilities:    
Accounts payable 3,796 1,993
Accrued expenses 2,134 2,627
Warrant liabilities 9,731 14,821
Accrued employee benefits 787 313
Deferred rent 40 3
Total Current Liabilities 16,488 19,757
Long term deferred rent 470 492
Total Liabilities 16,958 20,249
Commitments and Contingencies
Stockholders’ Equity:    
Preferred stock, $0.001 par value; 10,000,000 shares authorized, none issued and outstanding 0 0
Common stock, $0.001 par value; 250,000,000 shares authorized, 118,017,693 issued and 117,936,211 outstanding and 117,254,196 issued and 117,172,714 outstanding, respectively 118 117
Additional paid-in capital 177,331 175,762
Accumulated deficit (174,880) (172,034)
Total Synthetic Biologics, Inc. and Subsidiaries Equity 2,569 3,845
Non-controlling interest (1,808) (1,596)
Total Stockholders’ Equity 761 2,249
Total Liabilities and Stockholders' Equity $ 17,719 $ 22,498